Complicated urinary tract infections (cUTIs) represent an important and growing challenge in clinical practice, affecting individual patients’ health and quality of life while exerting a substantial burden on the healthcare system. Despite being common, these infections are underrecognized. The July …
Accurately distinguishing HER2-low and ultralow expression in metastatic breast cancer (mBC) is critical, yet it presents unique challenges for pathologists. Traditional binary HER2 classifications no longer meet clinical needs, as the availability of antibody-drug conjugates (ADCs) now depend on more …
Patients with chronic diseases frequently experience comorbid behavioral health disorders that complicate disease management, worsen outcomes, and increase health care utilization. Despite evidence linking psychiatric illnesses (e.g., depression, anxiety, bipolar disorder, schizophrenia) to poor adherence and higher mortality, behavioral health …
The emergence of HER2-low and ultralow classifications in mBC (mBC) is reshaping treatment options, offering new hope for patients who were once considered ineligible for targeted therapy. Yet many clinicians face uncertainty about how to appropriately define these new phenotypes …
This program highlights the essential role of shared decision-making (SDM) and motivational interviewing in caring for individuals with or at risk for hepatitis B (HBV), hepatitis C (HCV), and hepatitis D (HDV). Moving beyond traditional paternalistic models of care, SDM …
Obesity affects more than 44% of post-9/11 U.S. Veterans—far surpassing rates in the general population—and contributes substantially to cardiometabolic disease, osteoarthritis, chronic pain, sleep apnea, and type 2 diabetes. Despite strong evidence supporting effective treatments, clinical uptake remains suboptimal. Fewer …
This global discussion among experts in Asia, Europe, and North America focuses on reducing delays in treatment for hepatitis B (HBV), hepatitis C (HCV), and hepatitis D (HDV) by addressing current gaps in screening, including the underuse of evidence-based diagnostic …
Despite major advances in inflammatory bowel disease (IBD) management, real-world data show that many patients continue to experience suboptimal outcomes due to misaligned treatment goals, therapeutic inertia, and limited integration of novel therapies, particularly IL-23 inhibitors—into individualized care plans. While …
Primary Immunodeficiency (PI) disorders are a group of more than 180 inherited disorders, of the approximately 550 inborn errors of immunity (IEIs), that predispose affected patients to a variety of bacterial, viral, and fungal infections. Infections may be more prolonged …